These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6144610)

  • 1. Lack of initiating or promoting activity of six benzodiazepine tranquilizers in rat liver limited bioassays monitored by histopathology and assay of liver and plasma enzymes.
    Remandet B; Gouy D; Berthe J; Mazue G; Williams GM
    Fundam Appl Toxicol; 1984 Apr; 4(2 Pt 1):152-63. PubMed ID: 6144610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited in vivo bioassays on some benzodiazepines: lack of experimental initiating or promoting effect of the benzodiazepine tranquillizers diazepam, clorazepate, oxazepam and lorazepam.
    Mazue G; Remandet B; Gouy D; Berthe J; Roncucci R; Williams GM
    Arch Int Pharmacodyn Ther; 1982 May; 257(1):59-65. PubMed ID: 6126160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the hepatocarcinogenic peroxisome-proliferating hypolipidemic agents clofibrate and nafenopin on the rat liver cell membrane enzymes gamma-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis.
    Numoto S; Furukawa K; Furuya K; Williams GM
    Carcinogenesis; 1984 Dec; 5(12):1603-11. PubMed ID: 6149819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early stages of N-2-fluorenylacetamide-induced hepatocarcinogenesis in male and female rats and effect of gonadectomy on liver neoplastic conversion and neoplastic development.
    Katayama S; Ohmori T; Maeura Y; Croci T; Williams GM
    J Natl Cancer Inst; 1984 Jul; 73(1):141-9. PubMed ID: 6588222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An enhancing effect of the antihistaminic drug methapyrilene on rat liver carcinogenesis by previously administered N-2-fluorenylacetamide.
    Furuya K; Mori H; Williams GM
    Toxicol Appl Pharmacol; 1983 Aug; 70(1):49-56. PubMed ID: 6612738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing effect of butylated hydroxytoluene on the development of liver altered foci and neoplasms induced by N-2-fluorenylacetamide in rats.
    Maeura Y; Williams GM
    Food Chem Toxicol; 1984 Mar; 22(3):191-8. PubMed ID: 6538537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initiation of gamma-glutamyltranspeptidase positive foci in the rat liver by N-hydroxy-2-acetylaminofluorene. The effect of the sulfation inhibitor pentachlorophenol.
    Meerman JH
    Carcinogenesis; 1985 Jun; 6(6):893-7. PubMed ID: 2860981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of hepatocarcinogenesis by sequential administration of chemicals: summation versus promotion effects.
    Williams GM; Katayama S; Ohmori T
    Carcinogenesis; 1981; 2(11):1111-7. PubMed ID: 6119166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of various chemicals for initiating and promoting activities in a short-term in vivo system based on generation of hyperplastic liver nodules in rats.
    Tatematsu M; Hasegawa R; Imaida K; Tsuda H; Ito N
    Carcinogenesis; 1983; 4(4):381-6. PubMed ID: 6301702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of rat hepatocellular-altered foci by the liver tumor promoter phenobarbital: evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions.
    Watanabe K; Williams GM
    J Natl Cancer Inst; 1978 Nov; 61(5):1311-4. PubMed ID: 280716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of the anorectic agent 1,3-bis[2-cyano-5-(trifluoromethyl)-phenyl]triazene in in vitro and in vivo liver promoting assays.
    Maruyama H; Tanaka T; Williams GM
    Cancer Lett; 1988 May; 40(1):13-21. PubMed ID: 3370626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative kinetics of development of N-2-fluorenylacetamide-induced, altered (hyperplastic) hepatocellular foci resistant to iron accumulation and of their reversion or persistence following removal of carcinogen.
    Williams GM; Watanabe K
    J Natl Cancer Inst; 1978 Jul; 61(1):113-21. PubMed ID: 276621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine.
    Williams GM; Gebhardt R; Sirma H; Stenbäck F
    Carcinogenesis; 1993 Oct; 14(10):2149-56. PubMed ID: 8106178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different responses to phenobarbital promotion in the development of gamma-glutamyltranspeptidase-positive foci in the liver of rats initiated with diethylnitrosamine, N-hydroxy-2-acetyl-aminofluorene and aflatoxin B1.
    Shirai T; Imaida K; Ohshima M; Fukushima S; Lee MS; King CM; Ito N
    Jpn J Cancer Res; 1985 Jan; 76(1):16-9. PubMed ID: 2857671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical differentiation of gamma-glutamyltranspeptidase in focal lesions and in zone I of rat liver after treatment with chemical carcinogens.
    Fischer G; Lilienblum W; Ullrich D; Bock KW
    Carcinogenesis; 1986 Sep; 7(9):1405-10. PubMed ID: 2874897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of protein kinase C delta is associated with a delay in preneoplastic lesion development in diethylnitrosamine-induced rat hepatocarcinogenesis.
    La Porta CA; Comolli R
    Carcinogenesis; 1995 May; 16(5):1233-8. PubMed ID: 7767990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential observation of pathomorphologic alterations in preneoplastic lesions during the promoting stage of hepatocarcinogenesis and the development of short-term test system for hepatopromoters and hepatocarcinogens.
    Ito N; Tsuda H; Hasegawa R; Imaida K
    Toxicol Pathol; 1982 Feb; 10(2):37-47. PubMed ID: 28094708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced survival and absence of progressive growth of transplanted rat liver altered eosinophilic foci and neoplastic nodules in phenobarbital-treated rats.
    Mori H; Furuya K; Williams GM
    J Natl Cancer Inst; 1983 Oct; 71(4):849-54. PubMed ID: 6194334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of a promoting or sequential syncarcinogenic effect in rat liver by the carcinogenic hypolipidemic drug nafenopin given after N-2-fluorenylacetamide.
    Numoto S; Mori H; Furuya K; Levine WG; Williams GM
    Toxicol Appl Pharmacol; 1985 Jan; 77(1):76-85. PubMed ID: 3966244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on initiating activity of secondary bile acids for rat hepatocarcinogenesis].
    Kitazawa S
    Hokkaido Igaku Zasshi; 1993 Jan; 68(1):110-20. PubMed ID: 8095246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.